title: Recent Updates on Molecular Genetic Engineering Approaches and Applications of Human Therapeutic Proteins.
abstract: Therapeutic proteins are engineered proteins produced in the laboratory for pharmaceutical use. With the advent of recombinant DNA technology, the proteins can be generated in specific host cells under defined conditions. In the process of production of genetically engineered animals, the gene of interest can be added at a single cell stage to produce a cloned animal from genetically engineered cells. Several recombinant cytokines, clotting factors etc have been licensed and are currently being utilized for the treatment of cancer, infectious diseases, hemophilia, anemia, multiple sclerosis, and hepatitis B/C. Therapeutic proteins that are useful for human are successfully produced in poultry as well as in livestock animals. However, the fastest growing class of therapeutic proteins are antibodies especially monoclonal antibodies (mAb), the most important class of therapeutic protein with the potential to generate significant revolution in terms of clinical success rate. Here, we review the most recent clinical advances in the field of emerging and existing therapeutic proteins.
authors: Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh-202002, UP, India.
authors: Asim
authors: A
authors: Azhar
authors: Ejaj
authors: E
authors: Ahmad
authors: Qamar
authors: Q
authors: Zia
authors: Mohammad
authors: M
authors: Owais
authors: King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia.
authors: Ghulam Md
authors: GM
authors: Ashraf
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000235:genetics / Q000494:pharmacology; D016207:Cytokines / Q000235:genetics / Q000494:pharmacology; D003850:Deoxyribonuclease I / Q000235:genetics / Q000494:pharmacology; D005169:Factor VIII / Q000235:genetics / Q000494:pharmacology; D016179:Granulocyte Colony-Stimulating Factor / Q000235:genetics / Q000494:pharmacology; D006801:Humans; D007128:Immunoglobulin Fragments / Q000235:genetics / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000494:pharmacology; D007372:Interferons / Q000235:genetics / Q000494:pharmacology; D015202:Protein Engineering / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D011994:Recombinant Proteins / Q000235:genetics / Q000494:pharmacology*; D061905:Single-Domain Antibodies / Q000235:genetics / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000494:pharmacology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D007128:Immunoglobulin Fragments; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D061905:Single-Domain Antibodies; D016179:Granulocyte Colony-Stimulating Factor; D007334:Insulin-Like Growth Factor I; C078147:F8 protein, human; D005169:Factor VIII; D007372:Interferons; C087896:reteplase; D003850:Deoxyribonuclease I; C568813:dornase alfa; D010959:Tissue Plasminogen Activator
keywords: Chimeric antibodies; clotting factors; cytokines; hormones; medicinal chemistry; therapeutic proteins